NCT00004852

Brief Summary

The purpose of this study is to look at the safety and effectiveness of receiving lamivudine (3TC) once a day versus twice a day as part of an anti-HIV drug combination.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
5 countries

66 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 1999

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

March 2, 2000

Completed
1.5 years until next milestone

First Posted

Study publicly available on registry

August 31, 2001

Completed
Last Updated

June 24, 2005

Status Verified

August 1, 2000

First QC Date

March 2, 2000

Last Update Submit

June 23, 2005

Conditions

Keywords

HIV-1Drug Therapy, CombinationZidovudineDrug Administration ScheduleLamivudineGenotypePhenotypeReverse Transcriptase InhibitorsAnti-HIV AgentsViral Loadefavirenz

Interventions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients may be eligible for this study if they:
  • Are 18 years of age or older.
  • Are HIV-positive.
  • Have a viral load (level of HIV in the blood) of at least 400 copies/ml within 21 days of study entry.
  • Have a CD4 count greater than 100 cells/mm3 within 21 days of study entry.
  • Agree to practice abstinence or use effective barrier methods of birth control (or, if patient is a woman, unable to have children).

You may not qualify if:

  • Patients will not be eligible for this study if they:
  • Have taken any antiretroviral (anti-HIV) agent.
  • Are pregnant or breast-feeding.
  • Are unable to absorb food or have trouble taking medicines by mouth.
  • Abuse alcohol or drugs to an extent that may make study participation difficult.
  • Are not likely to be able to complete the 48 weeks of study treatment.
  • Have a history of pancreatitis (inflamed pancreas) or hepatitis within the last 6 months or any evidence of liver disease.
  • Have received an investigational vaccine within the past 3 months or have received gene therapy.
  • Have a severe medical condition such as diabetes or heart trouble.
  • Have been diagnosed with AIDS.
  • Have had radiation therapy or chemotherapy within 30 days of study entry, except for treatment of Kaposi's sarcoma.
  • Are taking medications that affect the immune system within 30 days of study entry.
  • Are taking medications that may interact with the study drugs.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (66)

Phoenix Body Positive

Phoenix, Arizona, 85016, United States

Location

Pacific Oaks Research

Beverly Hills, California, 90211, United States

Location

AIDS Healthcare Foundation

Los Angeles, California, 900276069, United States

Location

Tower ID Med Associates

Los Angeles, California, 90048, United States

Location

Davies Med Ctr / c/o HIV Institute

San Francisco, California, 94114, United States

Location

Kaiser Foundation Hospital

San Francisco, California, 94118, United States

Location

Harbor - UCLA Med Ctr

Torrance, California, 90509, United States

Location

Georgetown Univ Med Ctr

Washington D.C., District of Columbia, 20007, United States

Location

George Washington Univ Med Ctr

Washington D.C., District of Columbia, 20037, United States

Location

IDC Research Initiative

Altamonte Springs, Florida, 32701, United States

Location

Bach and Godofsky

Bradenton, Florida, 34205, United States

Location

TheraFirst Med Ctrs Inc

Fort Lauderdale, Florida, 33308, United States

Location

North Broward Hosp District

Fort Lauderdale, Florida, 33316, United States

Location

The Coleman Institute Inc

Fort Lauderdale, Florida, 33334, United States

Location

The Coleman Institute Inc

Ft. Pierce, Florida, 34950, United States

Location

Kaiser Permanente Infectious Diseases

Atlanta, Georgia, 30339, United States

Location

AIDS Research Alliance - Chicago

Chicago, Illinois, 60657, United States

Location

Infectious Disease of Indiana

Indianapolis, Indiana, 46218, United States

Location

Univ of Kentucky Med Ctr

Lexington, Kentucky, 40536, United States

Location

Tulane Univ School of Medicine

New Orleans, Louisiana, 70112, United States

Location

Boston Med Ctr / Evans - 556

Boston, Massachusetts, 021182393, United States

Location

Antibiotic Research Associates

Kansas City, Missouri, 64132, United States

Location

East Orange Veterans Administration Med Ctr

East Orange, New Jersey, 07018, United States

Location

ID Care Inc

New Brunswick, New Jersey, 08901, United States

Location

ID Care Inc

Princeton, New Jersey, 08540, United States

Location

ID Care Inc

Randolph Township, New Jersey, 07869, United States

Location

ID Care Inc

Somerville, New Jersey, 08876, United States

Location

Albany Med College / Div of HIV Medicine

Albany, New York, 12208, United States

Location

North Shore Univ Hosp / Div of Infectious Diseases

Manhasset, New York, 11030, United States

Location

St Vincents Hosp / Clinical Research Program

New York, New York, 10011, United States

Location

St Lukes / Roosevelt Hosp / HIV Center

New York, New York, 10019, United States

Location

Ohio State Univ Hosp Clinic

Columbus, Ohio, 432101228, United States

Location

Oklahoma State University / College of Osteopathic Medicine

Tulsa, Oklahoma, 74107, United States

Location

Associates in Med and Mental Health

Tulsa, Oklahoma, 74114, United States

Location

Miriam Hosp / Brown Univ

Providence, Rhode Island, 02906, United States

Location

Methodist Healthcare

Memphis, Tennessee, 38104, United States

Location

Univ of Tennessee

Memphis, Tennessee, 38163, United States

Location

Vanderbilt Univ Med Ctr

Nashville, Tennessee, 37203, United States

Location

Dr David Donnell

Dallas, Texas, 75219, United States

Location

Nelson-Tebedo Community Clinic

Dallas, Texas, 75219, United States

Location

Univ of Texas Med Branch

Galveston, Texas, 77555, United States

Location

Montrose Clinic

Houston, Texas, 77006, United States

Location

Baylor College of Medicine / Dept of Medicine

Houston, Texas, 770303498, United States

Location

Univ of Texas / Med School at Houston

Houston, Texas, 77030, United States

Location

Univ of Texas Health Sciences Ctr

San Antonio, Texas, 782847838, United States

Location

Hampton Roads Med Specialists

Hampton, Virginia, 23666, United States

Location

Hosp Muniz

Buenos Aires, Argentina

Location

CAICI

Rosario - Santa Fe, Argentina

Location

Universidade de Campinas

Campinas - SP, Brazil

Location

Hosp Evandro Chagas Fioernz

Manguinhos RJ, Brazil

Location

Hosp Univ Clementino Fraga Filho

Rio de Janeiro - RJ, Brazil

Location

Hosp Univ Pedro Ernesto / Univ Estadual do RJ

Rio de Janeiro - RJ, Brazil

Location

Hosp Sao Paulo da Universidade Federal de Sao Paulo

Sao Paulo - SP, Brazil

Location

Southern Alberta HIV Clinic / Foothills Hosp

Calgary, Alberta, Canada

Location

Saint Paul's Hosp

Vancouver, British Columbia, Canada

Location

Sunnybrook Health Science Centre

Toronto, Ontario, Canada

Location

Toronto Gen Hosp

Toronto, Ontario, Canada

Location

Wellesley/Central Site / St Michael's Hospital

Toronto, Ontario, Canada

Location

Clinique Medicale du Quartier Latin

Montreal, Quebec, Canada

Location

Clinique Medicale L'Actuele

Montreal, Quebec, Canada

Location

Centre Hospitalier Universitaire de Quebec

Ste Foy, Quebec, Canada

Location

Caguas Regional Hosp

Caguas, 00726, Puerto Rico

Location

Hosp San Cristobal-Edif A

Cotto Laurel, 00780, Puerto Rico

Location

Carlos Leon-Valiente MD

Guaynabo, 00966, Puerto Rico

Location

Ramon Ramirez Ronda MD

Mayagüez, 00680, Puerto Rico

Location

San Juan AIDS Program

Santurce, 00908, Puerto Rico

Location

MeSH Terms

Conditions

HIV Infections

Interventions

efavirenzLamivudineZidovudine

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System Diseases

Intervention Hierarchy (Ancestors)

ZalcitabineDeoxycytidineCytidinePyrimidine NucleosidesPyrimidinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsDeoxyribonucleosidesNucleosidesNucleic Acids, Nucleotides, and NucleosidesDideoxynucleosidesThymidine

Study Design

Study Type
interventional
Phase
phase 2
Masking
DOUBLE
Purpose
TREATMENT
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

March 2, 2000

First Posted

August 31, 2001

Study Start

September 1, 1999

Last Updated

June 24, 2005

Record last verified: 2000-08

Locations